Budget Impact Analysis of Perampanel for Adjunctive Treatment in Epilepsy Patients 12 Years of Age and Older for Partial Onset Seizures With or Without Secondary Generalization and Primary Generalized Tonic-Clonic Seizures in the Russian Federation

Mkrtchyan, V. R.; Сергеев, А. М.; Pochigaeva, Ksenia; Shpak, I. A.

doi:10.17749/2070-4909.2016.9.2.028-037

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), а также в ряде случаев -хирургическое лечение [8][9][10]. Противоэпилептические лекарственные средства снижают возбудимость нейронов эпилептического очага, стабилизируют мембранные потенциалы этих клеток, что приводит к уменьшению количества спонтанных разрядов и, соответственно, к снижению количества приступов [11][12][13]. Хирургия направлена на удаление патологически функционирующих участков коры больших полушарий головного мозга, которые являются источником аномальных электрических импульсов, приводящих к судорогам [10,14].…”

unclassified

Cell Therapy of Epilepsia. Clinical and Immunological Aspects

Dokukina¹,

Потапнев²,

Kosmacheva³

et al. 2018

Èpilepsiâ paroksizmalʹnye sostoâ.

View full text Add to dashboard Cite

show abstract

unclassified

Cell Therapy of Epilepsia. Clinical and Immunological Aspects

Dokukina¹,

Потапнев²,

Kosmacheva³

et al. 2018

Èpilepsiâ paroksizmalʹnye sostoâ.

View full text Add to dashboard Cite

show abstract

Perampanel in the treatment of patients with epilepsy

Rider

2017

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Development of new antiepileptic drugs (AED) does not stop due to the fact that the number of patients with pharmacoresistant epilepsy remains at about 30%. One of the newest AEDs is perampanel (PER), a selective, non-competitive AMPA receptor antagonist to target post-synaptic glutamate transmission. PER is approved in the Russian Federation as adjunctive treatment for focal seizures with or without secondarily generalized seizures and for primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) in patients with epilepsy aged ≥12 years. The drug is effective and well-tolerated in the dose of 4-8 mg/day, and most side effects are dose-dependent. The high efficacy of PER combined with the good tolerability, absence of life-threatening adverse reactions and convenient intake allow us to recommend PER as the first choice additional drug in treatment of patients with epilepsy.

show abstract